Article Figures & Data
Tables
- Table 1.
Demographic, disease characteristics, and comorbidities of the Latin America countries and the global ASAS-COMOSPA study. All values are %, except for n (%) for categorical or mean (SD) for continuous variables.
Characteristics ASAS-COMOSPA Latin America Argentina Colombia Mexico No. patients 3984 390 236 85 69 Male 65.0 63.8 61.9 60.0 75.4 Age, yrs 44 (14) 44.6 (14.7) 45.4 (14.5) 44.1 (13.9) 42.6 (16.3) Education level, university 42.4 42.6 34.7 50.6 59.4 Smoking status, current 23.0 16.7 22.0 10.6 5.8 Disease duration, yrs 8.2 (9.4) 7.0 (8.1) 6.7 (8.3) 5.2 (5.6) 9.3 (8.7) Disease symptoms Axial involvement 88.7 84.2 78.3 92.9 94.0 Arthritis 56.4 73.9 77.0 70.6 67.2 Enthesitis 38.0 62.5 57.9 77.6 59.7 Dactylitis 15.6 23.8 25.5 24.7 16.4 Uveitis 20.3 15.8 14.9 11.8 23.9 Psoriasis 22.5 23.0 33.2 4.7 10.4 IBD 5.2 3.3 3.4 3.5 3.0 ASDAS-CRP 2.0 (1.1) 1.9 (1.1) 1.8 (1.1) 2.0 (1.0) 1.8 (1.4) BASFI 3.0 (2.7) 3.4 (2.8) 3.1 (2.8) 4.3 (2.2) 3.7 (3.0) NSAID use, last 3 mos 67.8 71.8 71.9 68.2 76.1 Methotrexate, ever 32.7 47.6 48.7 42.3 50.7 Sulfasalazine, ever 43.9 43.5 25.4 70.2 87 Biological (TNFi), ever 43.9 34.1 35.6 36.4 26.1 ASAS-COMOSPA: Assessment of SpondyloArthritis international Society of COMOrbidities in SpA; SpA: spondyloarthritis; IBD: inflammatory bowel disease; ASDAS-CRP: Ankylosing Spondylitis Disease Activity Score–C-reactive protein; BASFI: Bath Ankylosing Spondylitis Functional Index; NSAID: nonsteroidal antiinflammatory drug; TNFi: tumor necrosis factor inhibitor.
- Table 2.
Observed prevalence of AHT in the ASAS-COMOSPA study (Latin America) compared with the expected prevalence in the general population and the prevalence of Global ASAS-COMOSPA for reference.
Sex Age, yrs Observed LA ASAS-COMOSPA Expected General Population Prevalence (%) SRR (CI 95%) Global ASAS-COMOSPA n (%) n (%) Men ≤ 24 0 0 NA — 3 2.65 25–34 4 12.5 3.6 3.4 49 8.47 35–44 2 8.7 7.8 1.1 152 24.4 45–54 6 28.5 14.6 1.9 247 43.3 55–64 4 57.1 30.9 1.8 240 61.1 ≥ 65 7 70.0 NA — 201 84.1 Total 23 22.3 12.9 1.4 (0.9–2.2) 892 34.4 Women ≤ 24 0 0 NA — 0 0 25–34 1 8.3 0.9 9.2 17 7.4 35–44 2 15.3 3.8 4.0 61 16.8 45–54 5 41.6 17.0 2.4 132 36.8 55–64 1 11.1 34.3 0.3 104 45.6 ≥ 65 1 25.0 NA — 102 68.6 Total 10 19.6 12.1 1.5 (0.8–2.8) 416 29.8 Total (men/women) 33 21.4 12.5 1.5 (1.0–2.1) 1308 33.1 Hypertension defined as a history of hypertension or antihypertensive therapy use or blood pressure ≥ 140/90 mm Hg at the study visit. LA: Latin America (data confined to patients from Colombia and Mexico); SRR: standardized risk ratio (ratio calculated for the age of 25–64 yrs); n: number with a diagnosis of arterial hypertension (AHT) in each sex and age group; ASAS-COMOSPA: Assessment of SpondyloArthritis international Society of COMOrbidities in SpA; SpA: spondyloarthritis; NA: not available.
- Table 3.
Observed prevalence of TB in the ASAS-COMOSPA study (Latin America) compared with the expected prevalence in the general population and the prevalence of Global ASAS-COMOSPA for reference.
Sex Age, yrs Observed LA ASAS-COMOSPA Expected General Population Prevalence (%) SRR (CI 95%) Global ASAS-COMOSPA n (%) n (%) Men 20–24 0 0 0.29 — 0 0 25–34 0 0 0.21 — 16 2.7 35–44 2 3.3 0.23 14.3 15 2.4 45–54 2 4.3 0.40 10.7 18 3.1 55–64 2 7.4 0.73 10.1 12 3.1 ≥ 65 1 4.0 1.14 3.5 17 7.1 Total men 7 2.8 0.41 6.8 (3.2–13.9) 78 3.0 Women 20–24 0 0 0.22 — 0 0 25–34 0 0 0.13 — 1 0.4 35–44 2 5.6 0.15 37.3 4 1.1 45–54 1 2.8 0.19 14.7 6 1.7 55–64 2 7.4 0.37 20.0 11 4.8 ≥ 65 1 7.1 0.41 17.3 1 0.7 Total women 6 4.2 0.23 18.2 (8.5–40.6) 23 1.6 Total (men/women) 13 3.3 0.32 10.3 (6.1–17.8) 101 2.5 LA: Latin America; TB: tuberculosis; SRR: standardized risk ratio; ASAS-COMOSPA: Assessment of SpondyloArthritis international Society of COMOrbidities in SpA; SpA: spondyloarthritis.
- Table 4.
Observed prevalence of all malignancies in the ASAS-COMOSPA study (Latin America) compared with the expected prevalence in the general population and prevalence of Global ASAS-COMOSPA for reference.
Sex Age, yrs Observed LA ASAS-COMOSPA Expected General Population Prevalence (%) SRR (CI 95%) Global ASAS-COMOSPA n (%) n (%) Men 20–39 0 0 0.41 — 4 0.3 40–44 0 0 0.76 — 2 0.6 45–49 0 0 1.29 — 5 1.6 50–54 1 5.0 2.39 2.0 8 3.0 55–59 1 7.6 4.11 1.8 9 3.9 60–64 1 7.1 6.49 1.0 9 5.4 65–70 1 8.3 9.28 0.8 13 11.3 ≥ 70 1 7.6 15.17 0.5 27 21.9 Total men 5 2.0 2.41 0.8 (0.3–1.9) 77 2.9 Women 20–39 0 0 0.54 — 6 1.2 40–44 0 0 1.91 — 3 1.6 45–49 1 4.3 2.70 1.5 4 2.2 50–54 2 15.3 3.53 4.3 11 6.0 55–59 2 13.3 4.49 2.9 6 4.6 60–64 1 8.3 5.90 1.4 10 10.0 65–70 0 0 6.98 — 4 4.8 ≥ 70 0 0 9.57 — 7 10.7 Total women 6 4.2 2.67 1.5 (0.7–3.4) 51 3.6 Total (men/women) 11 2.8 2.6 1.0 (0.6–1.9) 128 3.2 LA: Latin America; n: number with a diagnosis of malignancies in each sex and age group; ASAS-COMOSPA: Assessment of SpondyloArthritis international Society of COMOrbidities in SpA; SpA: spondyloarthritis; SRR: standardized risk ratio.
